Insights from MINDFuL Phase II Study Unveiled
MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated
INmune Bio, Inc. (NASDAQ: INMB), a pioneering company in the realm of inflammation and immunology, is making waves by presenting vital information regarding its MINDFuL Phase II study. This study delves into the participants' demographics and biomarker profiles of patients with early Alzheimer’s Disease (AD) during the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders in Vienna.
This annual conference, regarded as the largest Alzheimer’s gathering in Europe, serves as an ideal platform for disseminating crucial data. The poster discussed by INmune Bio highlights the baseline demographics and status of biomarkers at the time of enrollment in the trial specifically designed for individuals diagnosed with Mild Cognitive Impairment (MCI) and Mild Alzheimer’s Disease (mAD).
Study Overview and Participant Characteristics
The MINDFuL trial has enrolled 208 patients categorized into two groups: MCI (92 patients, accounting for 44%) and mild AD (116 patients, constituting 56%). The average age of these individuals hovers around 72, emphasizing the age-related nature of Alzheimer’s Disease. Each participant met stringent criteria linked to various biomarkers of inflammation, validating their condition further.
These biomarkers include hsCRP values exceeding 1.5 mg/L, an ESR above 10 mm/hr, HbA1c levels higher than 6.0%, or the presence of at least one APOE ?4 allele, all significant markers in gauging the inflammatory status of these patients. The trial employs a rigorous randomization method, with participants categorized 2:1 into groups receiving either XPro™ at a dosage of 1.0 mg/kg or a placebo via weekly subcutaneous injections over a span of 23 weeks.
Cognitive Measurements and Primary Endpoint
In this carefully structured trial, pivotal to success is the primary endpoint, which focuses on the changes from the baseline cognitive scores as assessed by the Early and Mild Alzheimer's Cognitive Composite (EMACC). This cognitive score evaluation was specifically tailored for objective measurement in early AD clinical trials, ensuring a reliable tracking mechanism for cognitive decline in participants.
Notably, initial EMACC scores revealed a higher baseline in MCI patients compared to their mild AD counterparts. This observation substantiates the tool's robustness and its valid alignment with other cognitive assessments such as the MMSE (Mini-Mental State Examination) and the CDR-SB (Clinical Dementia Rating Scale-Sum of Boxes).
Challenges in Patient Enrollment
It's important to acknowledge the enrollment process challenges faced by the MINDFuL trial, as evidenced by a significant screen failure rate of 72%. The predominant reason for exclusion stemmed from disease severity assessed through the screening MMSE, underscoring the critical threshold of patient qualification necessary for linking Alzheimer’s disease to possible treatment outcomes.
Expert Insights on Patient Cohorts
“Our preliminary data analysis presents a well-characterized group of individuals exhibiting early-stage Alzheimer’s Disease along with biomarker-confirmed inflammation that resonates with immune system dysfunction,” shared CJ Barnum, VP of CNS Drug Development at INmune Bio. He highlighted the significant presence of genetics among the trial participants, as 69.2% were identified as APOE ?4 carriers and 64.4% qualified based on more than one enrichment biomarker. This diversity in biomarker profiles is evenly spread across different genders and diagnostic categories, portraying a well-balanced representation.
Furthermore, patient characteristics regarding age, duration of the disease, and accompanying features mirror those observed in larger, successful Phase III trials for early AD, suggesting insights that could extend knowledge in treatment pathways.
Expectations and Upcoming Presentations
The MINDFuL trial has secondary endpoints encompassing various cognitive assessments, including the CDR-SB, E-Cog, activities of daily living (ADL), and neuropsychiatric evaluations. Noteworthy blood biomarker analyses and neuroimaging results are also anticipated as secondary metrics.
As the conference progresses, attendees will witness the presentation of baseline demographics and disease characteristics in poster format from April 4-5, contributing to the collective understanding and collaborative effort in Alzheimer’s research. The presentation, aptly titled “ALZHEIMER’S DISEASE (AD) AND IMMUNE DYSFUNCTION: BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS FROM A PHASE-2 STUDY OF XPRO1595 IN EARLY AD,” aims to further track the advancements in combating Alzheimer’s Disease.
Excitement builds around the expected topline results of the MINDFuL trial, slated to be shared in June, indicating a step closer to potential breakthroughs in the ongoing fight against Alzheimer’s Disease.
Frequently Asked Questions
What is the MINDFuL Phase II study about?
The MINDFuL Phase II study is focused on assessing the effectiveness of XPro™ in patients with early Alzheimer's Disease by measuring cognitive scores and evaluating the influence of inflammatory biomarkers.
When will the results of the MINDFuL study be released?
Topline results from the MINDFuL trial are anticipated to be reported in June.
How many patients are enrolled in the MINDFuL trial?
A total of 208 patients diagnosed with MCI and mild Alzheimer's Disease are enrolled in the study.
What are the primary and secondary endpoints of the study?
The primary endpoint focuses on changes in cognitive scores measured using the EMACC, while secondary endpoints include assessments such as the CDR-SB, E-Cog, and neuropsychiatric evaluations.
Where was INmune Bio presenting their research?
The research findings were presented at the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders in Vienna.
